Description: MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
Home Page: www.maatpharma.com
70 Avenue Tony Garnier
Lyon,
69007
France
Phone:
33 4 28 29 14 00
Officers
| Name | Title |
|---|---|
| Mr. Herve Affagard | CEO, Co-Founder & Director |
| Dr. Joel Dore Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Pierre Rimbaud | Co-Founder |
| Ms. Sian Crouzet | CFO & Financial Director |
| Ms. Carole Schwintner | Technology Director & Chief Technology Officer |
| Dr. Nathalie Corvaia Ph.D. | Chief Scientific Officer |
| Guilhaume Debroas Ph.D. | Head of Investor Relations |
| Dr. Emilie Plantamura | Head of Clinical Development |
| Mr. Jonathan Chriqui Pharm.D. | Chief Business Officer |
| Dr. Gianfranco Pittari M.D., Ph.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0895 |
| Price-to-Sales TTM: | 41.6009 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 54 |